Single User License
INR 136740
Site License
INR 273480
Corporate User License
INR 410220

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Ocular Hypertension-Pipeline Review, H2 2016

Ocular Hypertension-Pipeline Review, H2 2016


  Request for Sample Report

Executive Summary

Ocular Hypertension-Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Ocular Hypertension-Pipeline Review, H2 2016', provides an overview of the Ocular Hypertension pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Ocular Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ocular Hypertension and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Ocular Hypertension

The report reviews pipeline therapeutics for Ocular Hypertension by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Ocular Hypertension therapeutics and enlists all their major and minor projects

The report assesses Ocular Hypertension therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Ocular Hypertension

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Ocular Hypertension

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Ocular Hypertension pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 8

List of Figures 9

Introduction 10

Global Markets Direct Report Coverage 10

Ocular Hypertension Overview 11

Therapeutics Development 12

Pipeline Products for Ocular Hypertension-Overview 12

Pipeline Products for Ocular Hypertension-Comparative Analysis 13

Ocular Hypertension-Therapeutics under Development by Companies 14

Ocular Hypertension-Therapeutics under Investigation by Universities/Institutes 16

Ocular Hypertension-Pipeline Products Glance 17

Late Stage Products 17

Clinical Stage Products 18

Early Stage Products 19

Ocular Hypertension-Products under Development by Companies 20

Ocular Hypertension-Products under Investigation by Universities/Institutes 22

Ocular Hypertension-Companies Involved in Therapeutics Development 23

Aerie Pharmaceuticals, Inc. 23

Allergan Plc 24

Amakem NV 25

Bausch & Lomb Incorporated 26

Can-Fite BioPharma Ltd. 27

D. Western Therapeutics Institute, Inc. 28

F. Hoffmann-La Roche Ltd. 29

Inotek Pharmaceuticals Corporation 30

Ironwood Pharmaceuticals, Inc. 31

Kowa Company, Ltd. 32

Laboratoires Thea S.A. 33

Laboratorios Sophia S.A. de C.V. 34

Lee's Pharmaceutical Holdings Limited 35

Lexicon Pharmaceuticals, Inc. 36

NicOx S.A. 37

Ocular Therapeutix, Inc. 38

Otsuka Holdings Co., Ltd. 39

pSivida Corp. 40

Sanofi 41

Santen Pharmaceutical Co., Ltd. 42

Senju Pharmaceutical Co., Ltd. 43

Sylentis S.A.U. 44

ViSci Ltd. 45

Ocular Hypertension-Therapeutics Assessment 46

Assessment by Monotherapy Products 46

Assessment by Combination Products 47

Assessment by Target 48

Assessment by Mechanism of Action 50

Assessment by Route of Administration 52

Assessment by Molecule Type 54

Drug Profiles 56

(bimatoprost + brimonidine tartarate + timolol maleate)-Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

(bimatoprost + timolol maleate)-Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

(carteolol hydrochloride + latanoprost)-Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

(latanoprost + netarsudil mesylate)-Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

(latanoprost + timolol maleate)-Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

(latanoprost + trabodenoson)-Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

AMA-0076-Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

bamosiran-Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

bimatoprost-Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

bimatoprost SR-Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

DE-117-Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

Gene Therapy to Target Matrix Metalloproteinase 1 for Steroid Induced Glaucoma and Ocular Hypertension-Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

H-1129-Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

IWP-953-Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

latanoprost-Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

latanoprost-Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

latanoprost SR-Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

latanoprost SR-Drug Profile 79

Product Description 79

Mechanism Of Action 79

R&D Progress 79

latanoprost SR-Drug Profile 80

Product Description 80

Mechanism Of Action 80

R&D Progress 80

latanoprostene bunod-Drug Profile 81

Product Description 81

Mechanism Of Action 81

R&D Progress 81

levobetaxolol hydrochloride-Drug Profile 85

Product Description 85

Mechanism Of Action 85

R&D Progress 85

LX-7101-Drug Profile 86

Product Description 86

Mechanism Of Action 86

R&D Progress 86

MGV-354-Drug Profile 87

Product Description 87

Mechanism Of Action 87

R&D Progress 87

NCX-1653-Drug Profile 88

Product Description 88

Mechanism Of Action 88

R&D Progress 88

NCX-470-Drug Profile 89

Product Description 89

Mechanism Of Action 89

R&D Progress 89

NCX-667-Drug Profile 90

Product Description 90

Mechanism Of Action 90

R&D Progress 90

netarsudil mesylate-Drug Profile 91

Product Description 91

Mechanism Of Action 91

R&D Progress 91

OPA-6566-Drug Profile 96

Product Description 96

Mechanism Of Action 96

R&D Progress 96

piclidenoson-Drug Profile 97

Product Description 97

Mechanism Of Action 97

R&D Progress 97

PRO-067-Drug Profile 106

Product Description 106

Mechanism Of Action 106

R&D Progress 106

RG-4929-Drug Profile 107

Product Description 107

Mechanism Of Action 107

R&D Progress 107

ripasudil-Drug Profile 108

Product Description 108

Mechanism Of Action 108

R&D Progress 108

RO-5093151-Drug Profile 110

Product Description 110

Mechanism Of Action 110

R&D Progress 110

SAR-366234-Drug Profile 111

Product Description 111

Mechanism Of Action 111

R&D Progress 111

Sepetaprost-Drug Profile 112

Product Description 112

Mechanism Of Action 112

R&D Progress 112

SNJ-1656-Drug Profile 113

Product Description 113

Mechanism Of Action 113

R&D Progress 113

trabodenoson-Drug Profile 115

Product Description 115

Mechanism Of Action 115

R&D Progress 115

travoprost SR-Drug Profile 118

Product Description 118

Mechanism Of Action 118

R&D Progress 118

travoprost XR-Drug Profile 120

Product Description 120

Mechanism Of Action 120

R&D Progress 120

Ocular Hypertension-Dormant Projects 122

Ocular Hypertension-Discontinued Products 124

Ocular Hypertension-Product Development Milestones 125

Featured News & Press Releases 125

Jun 16, 2016: Aerie Pharmaceuticals Completes Enrollment of Rocket 4 Phase 3 Clinical Trial of Rhopressa (netarsudil ophthalmic solution) 0.02% 125

May 05, 2016: Aerie Pharmaceuticals Completes Enrollment of Mercury 1 Phase 3 Registration Trial of Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% 125

Apr 27, 2016: Ocular Therapeutix Completes End-of-Phase 2 Review with FDA for OTX-TP (Sustained Release Travoprost) for Glaucoma and Ocular Hypertension 126

Apr 26, 2016: Inotek Pharmaceuticals Announces Poster Presentations on Trabodenoson at the ARVO 2016 Annual Meeting 126

Apr 11, 2016: Inotek Pharmaceuticals Announces the Journal of Ocular Pharmacology and Therapeutics has Published its Phase 2 Data for Trabodenoson in Patients with Glaucoma and Ocular Hypertension 127

Mar 28, 2016: Aerie Pharmaceuticals Initiates Second Phase 3 Registration Trial of Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% 128

Mar 17, 2016: Aerie Pharmaceuticals Reports Update on Positive Safety Results for Rhopressa QD (netarsudil ophthalmic solution) 0.02% 128

Mar 03, 2016: Aerie Pharmaceuticals Announces Availability on Its Website of Abstracts to be Presented at the American Glaucoma Society 26th Annual Meeting 129

Feb 22, 2016: Aerie Pharmaceuticals Announces Four New Abstracts to be Presented at the American Glaucoma Society 26th Annual Meeting Next Week 130

Feb 17, 2016: Aerie Pharmaceuticals Reports Positive Rhopressa QD (netarsudil ophthalmic solution) 0.02% 12 Month Interim Safety Results for Rocket 2 131

Feb 16, 2016: Ocular Therapeutix Announces Phase 3 Clinical Development Plan for OTX-TP, an Innovative Therapy for Glaucoma and Ocular Hypertension 131

Oct 22, 2015: Ocular Therapeutix Reports on Topline Results of Phase 2b Glaucoma Clinical Trial 132

Oct 01, 2015: New Drug Application for Carteolol Hydrochloride/ Latanoprost, a Novel Combined Ophthalmic Solution, Submitted in Japan for the Treatment of Glaucoma and Ocular Hypertension 134

Sep 24, 2015: Aerie Pharmaceuticals Initiates Fourth Phase 3 Clinical Trial of Rhopressa 134

Sep 21, 2015: Aerie Pharmaceuticals Initiates First Phase 3 Registration Trial of Roclatan 135

Appendix 136

Methodology 136

Coverage 136

Secondary Research 136

Primary Research 136

Expert Panel Validation 136

Contact Us 136

Disclaimer 137

List of Figures

Number of Products under Development for Ocular Hypertension, H2 2016 12

Number of Products under Development for Ocular Hypertension-Comparative Analysis, H2 2016 13

Number of Products under Development by Companies, H2 2016 14

Comparative Analysis by Late Stage Development, H2 2016 17

Comparative Analysis by Clinical Stage Development, H2 2016 18

Comparative Analysis by Early Stage Products, H2 2016 19

Assessment by Monotherapy Products, H2 2016 46

Assessment by Combination Products, H2 2016 47

Number of Products by Top 10 Targets, H2 2016 48

Number of Products by Stage and Top 10 Targets, H2 2016 48

Number of Products by Top 10 Mechanism of Actions, H2 2016 50

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 50

Number of Products by Routes of Administration, H2 2016 52

Number of Products by Stage and Routes of Administration, H2 2016 52

Number of Products by Molecule Types, H2 2016 54

Number of Products by Stage and Molecule Types, H2 2016 54

List of Tables

Number of Products under Development for Ocular Hypertension, H2 2016 12

Number of Products under Development for Ocular Hypertension-Comparative Analysis, H2 2016 13

Number of Products under Development by Companies, H2 2016 14

Number of Products under Development by Companies, H2 2016 (Contd..1) 15

Number of Products under Investigation by Universities/Institutes, H2 2016 16

Comparative Analysis by Late Stage Development, H2 2016 17

Comparative Analysis by Clinical Stage Development, H2 2016 18

Comparative Analysis by Early Stage Development, H2 2016 19

Products under Development by Companies, H2 2016 20

Products under Development by Companies, H2 2016 (Contd..1) 21

Products under Investigation by Universities/Institutes, H2 2016 22

Ocular Hypertension-Pipeline by Aerie Pharmaceuticals, Inc., H2 2016 23

Ocular Hypertension-Pipeline by Allergan Plc, H2 2016 24

Ocular Hypertension-Pipeline by Amakem NV, H2 2016 25

Ocular Hypertension-Pipeline by Bausch & Lomb Incorporated, H2 2016 26

Ocular Hypertension-Pipeline by Can-Fite BioPharma Ltd., H2 2016 27

Ocular Hypertension-Pipeline by D. Western Therapeutics Institute, Inc., H2 2016 28

Ocular Hypertension-Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 29

Ocular Hypertension-Pipeline by Inotek Pharmaceuticals Corporation, H2 2016 30

Ocular Hypertension-Pipeline by Ironwood Pharmaceuticals, Inc., H2 2016 31

Ocular Hypertension-Pipeline by Kowa Company, Ltd., H2 2016 32

Ocular Hypertension-Pipeline by Laboratoires Thea S.A., H2 2016 33

Ocular Hypertension-Pipeline by Laboratorios Sophia S.A. de C.V., H2 2016 34

Ocular Hypertension-Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016 35

Ocular Hypertension-Pipeline by Lexicon Pharmaceuticals, Inc., H2 2016 36

Ocular Hypertension-Pipeline by NicOx S.A., H2 2016 37

Ocular Hypertension-Pipeline by Ocular Therapeutix, Inc., H2 2016 38

Ocular Hypertension-Pipeline by Otsuka Holdings Co., Ltd., H2 2016 39

Ocular Hypertension-Pipeline by pSivida Corp., H2 2016 40

Ocular Hypertension-Pipeline by Sanofi, H2 2016 41

Ocular Hypertension-Pipeline by Santen Pharmaceutical Co., Ltd., H2 2016 42

Ocular Hypertension-Pipeline by Senju Pharmaceutical Co., Ltd., H2 2016 43

Ocular Hypertension-Pipeline by Sylentis S.A.U., H2 2016 44

Ocular Hypertension-Pipeline by ViSci Ltd., H2 2016 45

Assessment by Monotherapy Products, H2 2016 46

Assessment by Combination Products, H2 2016 47

Number of Products by Stage and Target, H2 2016 49

Number of Products by Stage and Mechanism of Action, H2 2016 51

Number of Products by Stage and Route of Administration, H2 2016 53

Number of Products by Stage and Molecule Type, H2 2016 55

Ocular Hypertension-Dormant Projects, H2 2016 122

Ocular Hypertension-Dormant Projects (Contd..1), H2 2016 123

Ocular Hypertension-Discontinued Products, H2 2016 124

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Aerie Pharmaceuticals, Inc.

Allergan Plc

Amakem NV

Bausch & Lomb Incorporated

Can-Fite BioPharma Ltd.

D. Western Therapeutics Institute, Inc.

F. Hoffmann-La Roche Ltd.

Inotek Pharmaceuticals Corporation

Ironwood Pharmaceuticals, Inc.

Kowa Company, Ltd.

Laboratoires Thea S.A.

Laboratorios Sophia S.A. de C.V.

Lee's Pharmaceutical Holdings Limited

Lexicon Pharmaceuticals, Inc.

NicOx S.A.

Ocular Therapeutix, Inc.

Otsuka Holdings Co., Ltd.

pSivida Corp.

Sanofi

Santen Pharmaceutical Co., Ltd.

Senju Pharmaceutical Co., Ltd.

Sylentis S.A.U.

ViSci Ltd.

Ocular Hypertension Therapeutic Products under Development, Key Players in Ocular Hypertension Therapeutics, Ocular Hypertension Pipeline Overview, Ocular Hypertension Pipeline, Ocular Hypertension Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com